ALN-Cytotoxic Chemotherapy

ALN-Cytotoxic Chemotherapy is an investigational cancer therapeutic developed by Alnair Therapeutics using its proprietary Alnair Lactate-reacting Nanoparticle (ALN) platform. The drug utilizes mesoporous silica nanoparticles (MSNs) to encapsulate cytotoxic chemotherapy agents. The MSN surface is modified with a lactate-reactive "cap" that incorporates the enzyme lactate oxidase and a peroxide-sensitive linker. This system is designed to exploit the Warburg effect, characterized by high lactate concentrations in the tumor microenvironment (TME). When the nanoparticles reach the TME, lactate oxidase converts local lactate into hydrogen peroxide, which triggers the cleavage of the peroxide-sensitive linker and the subsequent release of the chemotherapy payload directly at the tumor site. This targeted delivery mechanism is intended to improve the therapeutic index of conventional chemotherapy by increasing intratumoral concentration while reducing systemic exposure and associated toxicities. The program is currently in IND-enabling studies for breast cancer, ovarian cancer, and sarcoma.

Other names

Alnair Lactate-reacting Nanoparticle-Cytotoxic Chemotherapy